Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Multiple Sclerosis
      • Systemic Sclerosis
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
      • Cryopreservation of allogenic HCT grafts does not adversely impact early post-HCT outcomes
      • Precision medicine initiative uses whole genome sequencing to identify novel prognostic signatures and the impact of genomic subgroups in MDS allogeneic HCT patients
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
      • Advances in HCT Over Time
      • HCT Graft Source Selection: Cord Blood
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • MDS
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
  • Multiple Sclerosis
  • Systemic Sclerosis
Research Spotlight
  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • Systemic Sclerosis
  • Email
  • Print This Page

Systemic Sclerosis

Systemic sclerosis (SS) or scleroderma is a rare autoimmune disease affecting approximately 50 per 100,000 people in the United States. [1] It is characterized by debilitating effects on the connective tissue and various internal organs, caused by genetic and environmental predispositions. [2]

The use of autologous or allogeneic hematopoietic cell transplantation (HCT) is being considered for the treatment of SS. Preclinical and clinical studies suggest that high-dose immunotherapy alongside allogeneic HCT may improve outcomes. [3]

Risks related to the treatment regimen, graft-versus-host disease (GVHD), relapse and overall transplant eligibility must be weighed when choosing the best option and stem cell source for transplant. [3]

Advances

Risks for specific autoimmune, rheumatic diseases prove challenging due to the nature of the treatment. Research continues to expand the scope of HCT with a focus on:

  • Clinical trials specifically for SS focusing on the long-term effects of HCT, pharmacokinetics of cyclophosphamide, genetic expression and signatures, immunophenotypes, antibody repertoire, autoantibody profiles, and proteomics of SS [4] 

  • Post-transplant cyclophosphamide (PTCy) as treatment for GVHD [4] 

  • Allogeneic HCT versus autologous HCT [4]

Outcomes

Review outcomes for HCT in patients with SS below.

Figure 1. Event-free and Overall Survival from ASTIS Trial, 2001 – 2009 [5]

systemic sclerosis figure 1

Figure 2. Outcomes Following HCT for Multiple Sclerosis (MS), Systemic Sclerosis (SS) and Crohn’s Disease (CD), Blood Advances, 1994-2015 [6]

systemic sclerosis figure 2

Referral Timing Guidelines

These guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation.

Transplant Consultation Guidelines: Systemic Sclerosis

HCT consultation should take place:

  • At the time of diagnosis or with diffuse disease

  • With increasing skin tightness score (modified Rodnan skin score, [mRSS])  

  • Evidence of decrease ( < 80%) in % predicted pulmonary function tests: forced vital capacity (FVC) or/and diffusion capacity (DLCO)

Download as a slide (PPT)

View complete Referral Timing Guidelines

References

  1. Zhong L, Pope M, Shen Y, Hernandez JJ, Wu L. Prevalence and incidence of systemic sclerosis: A systematic review and meta-analysis. Int J Rheum Dis. 2019;22(12):2096-2107. doi:10.1111/1756-185X.13716.
  2. Asano Y. Systemic sclerosis. The Journal of Dermatology. 2018;45(2):128-138. doi:10.1111/1346-8138.14153.
  3. Sullivan KM, Sarantopoulos S. Allogeneic HSCT for autoimmune disease: a shared decision. Nature reviews Rheumatology. 2019;15(12):701-702. doi:10.1038/s41584-019-0306-7.
  4. Sullivan, K. Stem cell transplantation for scleroderma: results and research. Oral presentation at Vanderbilt Rheumatology Grand Rounds. September, 2021. Nashville, TN.
  5. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490-2498. doi:10.1001/jama.2014.6368.
  6. Snowden JA, Badoglio M, Labopin M, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Advances. 2017;1(27):2742-2755. doi:10.1182/bloodadvances.2017010041.
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2022 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright